RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Double-Barreled CAR-T attack on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study tests a new cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has returned or not responded to treatment and has spread outside the bone marrow. The main goal is to check the safety of this ap…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 05:56 UTC
-
New CAR-T therapy aims to outperform standard care in Hard-to-Treat myeloma
Disease control Recruiting nowThis study compares a new CAR-T cell therapy called arlocabtagene autoleucel (arlo-cel) with standard treatments for adults whose multiple myeloma has returned or stopped responding to prior therapy. About 440 participants will receive either the CAR-T cells or standard regimens.…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for Tough-to-Treat blood cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called F182112 against standard treatments for people with multiple myeloma that has returned or stopped responding to prior therapies. About 261 adults will be randomly assigned to receive either F182112 or usual care. The main goal is to see if F1821…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Double-Pronged attack: new CAR-T therapy targets stubborn myeloma tumors
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cancer cells. It is for people whose multiple myeloma has come back or stopped responding to treatment and has spread to tissues outside the bone marrow. The main goal i…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 20, 2026 11:53 UTC